Abstract Zolbetuximab is a first-in-class chimeric (mouse/human) monoclonal antibody targeted to the tight junction protein claudin 18.2 (CLDN18.2), an emerging biomarker in gastric/gastroesophageal …

VYLOY® (zolbetuximab-clzb) is a first-line FDA-approved monoclonal antibody that targets CLDN18.2 in advanced* G/GEJ cancer.1,4,5 According to estimates from two global Phase 3 studies, 38% of …

Zolbetuximab, sold under the brand name Vyloy, is a monoclonal antibody used for the treatment of gastric cancer. [4] It is a claudin 18.2-directed cytolytic antibody against isoform 2 of Claudin-18. [4]

Zolbetuximab-clzb works by binding to a protein called CLDN18.2, which some cancer cells produce in large amounts. This helps the immune system find and attack the cancer cells. Zolbetuximab-clzb …

Anti-Zolbetuximab Antibody (34E11), mAb, Mouse (GenScript, A02260) exhibited non-inhibitory properties, whereas Anti-Zolbetuximab Antibody (9C9), mAb, Mouse (GenScript, A02261) …

The following product was used in this experiment: Zolbetuximab Chimeric Recombinant Human Monoclonal Antibody from Thermo Fisher Scientific, catalog # MA5-42158, RRID AB_2911301.

On October 18, 2024, the Food and Drug Administration approved zolbetuximab-clzb (Vyloy, Astellas Pharma US, Inc.), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, with fluoropyrimidine- and …

Zolbetuximab, also known as IMAB362 or claudiximab, is an anti-Claudin 18.2 antibody that targets pancreatic ductal adenocarcinoma (PDAC) cancer cells and induces cytotoxicity through antibody …

16 hours ago · Gastric cancer remains a major global health challenge with few durable treatments, and claudin-18.2 (CLDN18.2) has emerged as an attractive therapeutic target, highlighted by the modest …

Dec 12, 2024 · FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma What is the potential role for zolbetuximab-clzb in the treatment of locally …